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ABSTRACT 
Objective: To develop a model to predict annual hospital costs for patients with established renal 
failure, taking into account the effect of patient and treatment characteristics of potential relevance for 
conducting an economic evaluation, such as age, comorbidities and time on treatment. The analysis 
focuses on factors leading to variations in inpatient and outpatient costs and excludes fixed costs 
associated with dialysis, transplant surgery and high cost drugs. 
Methods: Annual costs of inpatient and outpatient hospital episodes for patients starting renal 
replacement therapy in England were obtained from a large retrospective dataset. Multiple imputation 
was performed to estimate missing costs due to administrative censoring. Two-part models were 
developed using logistic regression to first predict the probability of incurring any hospital costs 
before fitting generalised linear models to estimate the level of cost in patients with positive costs. 
Separate models were developed to predict inpatient and outpatient costs for each treatment modality. 
Results: Data on hospital costs were available for 15,869 incident dialysis patients and 4,511 incident 
transplant patients. The two-part models showed a decreasing trend in costs with increasing number of 
years on treatment, with the exception of dialysis outpatient costs. Age did not have a consistent effect 
on hospital costs, however, comorbidities such as diabetes and peripheral vascular disease were strong 
predictors of higher hospital costs in all four models. 
Conclusion: Analysis of patient-level data can result in a deeper understanding of factors associated 
with variations in hospital costs and can improve the accuracy with which costs are estimated in the 
context of economic evaluations. 
 
Key words: hospital costs, established renal failure, regression, patient-level data, two-part model 
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INTRODUCTION 
Analysts involved in carrying out economic evaluations in healthcare are accustomed to expending 
considerable effort and resources to identify, collect, extrapolate and synthesise data to fully quantify 
the health consequences associated with different treatment approaches. However, when it comes to 
estimating costs, it is not uncommon to rely on readily available average unit costs that are assumed to 
apply uniformly to all patients or remain constant over time. If appropriate data sources can be 
identified, it would be beneficial to develop more precise ways to estimate the costs of managing 
patients with specific diseases and to explore in greater detail whether costs vary with patient and 
treatment characteristics of interest.  
Treatment options for patients with established renal failure (ERF) include dialysis and 
transplantation. For many patients, transplantation can result in increased life expectancy and better 
quality of life compared to chronic dialysis [1]. Treatment of ERF is resource intensive for the health 
service. While costs of dialysis and transplantation may be comparable in the first year of treatment, 
costs for transplant recipients following surgery drop considerably in subsequent years, while the cost 
of maintenance dialysis sessions remains constant [2]. In England, payment to providers for dialysis is 
covered under a fixed national tariff as part of the Payment by Results (PbR) system. A similar 
approach is underway to introduce a fixed tariff for kidney transplant surgery. However beyond the 
provision of dialysis and transplant surgery, patients with ERF may incur additional hospital costs for 
monitoring of their condition, management of comorbidities or infections, maintenance of vascular 
access or post-operative follow-up. More than half of patients starting renal replacement therapy 
(RRT) have one or more comorbidities [3] which, alongside other factors such as age, may lead to 
variations in hospitalisation rates [4].  
As part of the Access to Transplantation and Transplant Outcome Measures (ATTOM) study, an 
economic evaluation is being developed to compare alternative schemes for allocating kidneys to 
patients with ERF who are awaiting transplantation in the United Kingdom. Different approaches to 
kidney allocation can impact the length of time that patients with different characteristics will spend 
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on dialysis. This in turn can have an impact on the level of costs incurred. The objective of the current 
analysis is to develop a model to predict hospital inpatient and outpatient costs for patients with ERF, 
taking into account relevant patient and treatment characteristics such as age, comorbidities and time 
on treatment. The analysis will focus on characterising variations in hospital costs and therefore 
exclude fixed costs associated with routine dialysis, transplant surgery and high cost drugs. The 
approach to this analysis is guided by the intended use of the results as inputs for an economic 
evaluation that will compare the costs and consequences of alternative kidney allocation schemes.  
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METHODS 
Data source 
In England, all admissions to NHS hospitals are captured in the Hospital Episodes Statistics (HES) 
dataset. Patient demographics and information about type and length of stay are collected during a 
patient's time at hospital and are submitted to allow hospitals to be paid for the care they deliver [5]. 
Data on inpatient admissions have been routinely captured in HES since 1998 and outpatient 
attendances since 2003 [6]. The UK Renal Registry (UKRR) collects data provided by renal centres 
on all incident renal replacement therapy (RRT) patients, including demographics, comorbidity and 
treatment information [7]. In 2011, a pilot study was carried out in which UKRR data was linked to 
HES data for incident patients ≥18 years of age who started dialysis or received a kidney transplant 
between 2002 and 2006. HES only began collection of outpatient attendances in April 2003, therefore 
the sample for this analysis was restricted to those patients who started RRT between April 2003 and 
December 2006. The linked dataset captured hospital episodes until the end of December 2009 [6].  
Linkage of HES data to UKRR data enhances the variables available in the separate datasets and 
facilitates analysis of hospital episodes by RRT modality.  Taking the start of dialysis or date of 
transplant surgery as the index date, annual costs for each patient were generated by applying the 
appropriate 2011-12 PbR tariff to each inpatient admission (based on healthcare resource group) or 
outpatient appointment (based on treatment function code) [8] . Four separate datasets were created to 
capture dialysis inpatient, dialysis outpatient, transplant inpatient, and transplant outpatient costs in 
order to allow for the effect of explanatory variables to differ between regression models depending 
on treatment modality or type of hospital activity. The datasets included all inpatient admissions and 
outpatient appointments for any reason except routine dialysis or kidney transplant surgery. High cost 
drugs such as immunosuppressants following transplant surgery or drugs to treat renal anaemia were 
not captured in the dataset. The analysis therefore includes hospital costs that may not be specifically 
related to the management of patients’ ERF. It was not considered feasible to distinguish between 
hospital episodes that were related versus those that were unrelated to the management of ERF in the 
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current analysis. However in economic evaluations, the focus is on the difference in costs between 
alternative strategies, therefore the inclusion of both related and potentially unrelated costs is 
appropriate, provided the same approach is taken for both the dialysis and transplant datasets. 
Administrative censoring 
Linkage of the HES and UKRR datasets came to an end in December 2009 and therefore no further 
data on hospital episodes were available beyond this date. This means that in any given year, some 
patients may only have observed costs for a portion of the year due to administrative censoring. 
Rather than exclude these patients from the analysis, multiple imputation was performed to predict 
costs in the year that administrative censoring occurred under an assumption that data were missing at 
random (MAR). In the first instance, costs were imputed for the full year in which administrative 
censoring took place. However, since observed costs were available in these patients for part of the 
year up until the day of censoring, an additional step was taken to generate a hybrid imputed cost in 
order to make use of as much observed data as possible. Hybrid imputed costs were generated by 
using the imputed cost for the full year to calculate an imputed cost per day and multiplying this by 
the number of unobserved days for that year, to which the observed costs up until the day of censoring 
were then added.  
Model development 
Hospital costs in all four datasets were positively skewed with a varying proportion of zero-cost 
patients who had no inpatient admissions or outpatient visits in a given year. In order to accommodate 
these characteristics of the data, a two-part model approach for the regression analyses was taken [9-
11]. Part one involved using logistic regression analysis to predict whether or not patients would incur 
any hospital costs. Part two involved fitting a generalised linear model (GLM) for those patients with 
positive costs [12,13]. The cluster option was used to take into account the dependence between 
multiple observations (years of cost data) for the same patient.   
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Initially age, sex, treatment modality, year since starting RRT, and co-morbidities were all entered 
into the regression models. Dummy variables were also entered for events including renal recovery, 
transplant and death in the dialysis models and for graft failure and death in the transplant models.  
Since costs are expected to be elevated for several months prior to death, inclusion of a dummy 
variable only in the year of death would not capture the full impact of this event on costs in patients 
who die at the beginning of the year. Therefore, an additional variable was created to indicate if death 
occurred in the first half of the following year. Backwards elimination was used to inform variable 
selection using a P-value threshold of 0.2 [14]. 
Model performance was assessed by comparing predicted and observed mean costs and calculating 
the root-mean-square error (RMSE) [10]. In addition, models that were developed based on multiply 
imputed values were compared to the results of complete-case analyses to provide reassurance of the 
validity of the MAR assumption. 
All analyses were conducted in Stata (Version 13, Stata Corp, College Station, Texas, USA). 
  
8 
 
RESULTS 
Data on inpatient admissions and outpatient appointments during the first year after initiation of RRT 
were available for 15,869 dialysis patients and 4,511 transplant patients. Administrative censoring 
occurred in approximately 11% of transplant patients in the first year after surgery and increased to 
more than 50% by year six. In contrast, no administrative censoring was present in the first three years 
of the dialysis patient sample, but ranged between 20% and 50% in years three through six. Tables 1a 
and 1b summarise the number of patients included in the dataset by number of years following 
initiation of RRT. 
Table 1a Dialysis dataset: number of patients by years on dialysis  
Dialysis patients 
Years 
on 
dialysis 
With 
complete year 
costs 
With part-year costs due to TOTAL 
PATIENTS Death Transplant Recovered  Admin censoring  
1 11,894 (75%) 2,798 (17%) 750 (5%) 427 (3%) 0 (0%) 15,869 
2 9,472 (80%) 1,488 (12%) 803 (7%) 123 (1%) 0 (0%) 11,886 
3 7,501 (79%) 1,246 (13%) 634 (7%) 84 (1%) 0 (0%) 9,465 
4 4,205 (56%) 1,063 (14%) 476 (6%) 40 (1%) 1,713 (23%) 7,497 
5 1,932 (48%) 659 (16%) 248 (6%) 31 (1%)  1,188 (29%) 4,058 
6 596 (33%) 274 (15%) 101 (6%) 5 (0%) 823 (46%) 1,799 
 
Table 1b Transplant dataset: number of patients by years following transplant  
Transplant patients 
Years 
following 
transplant 
With complete 
year costs 
With part-year costs due to 
TOTAL 
PATIENTS Graft failure Death Admin censoring 
1 3,625 (80%) 266 (6%) 122 (3%) 498 (11%) 4,511 
2 2,881 (80%) 116 (3%) 33 (1%) 585 (16%) 3,615 
3 2,150 (75%) 48 (2%) 35 (1%) 644 (22%) 2,877 
4 1,355 (63%) 38 (2%) 22 (1%) 735 (34%) 2,150 
5 717 (53%) 16 (2%) 17 (1%) 605 (44%) 1,355 
6 239 (33%) 9 (1%) 21 (3%) 448 (63%) 717 
 
 
Part one: logistic regression analyses 
Excluding patients with only part-year cost data, the proportion of patients with zero costs in the first 
year of RRT was lower in the outpatient setting (2% for dialysis patients and 1% for transplant 
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patients) than in the inpatient setting (24% for dialysis patients and 27% for transplant patients). 
Logistic regression analyses showed that, compared to the first year of RRT, the odds of incurring any 
hospital costs in subsequent years was lower, with the exception of outpatient appointments for 
transplant patients (Tables 2a and 2b).  
The presence of comorbidities was associated with higher odds of incurring inpatient costs in both 
dialysis and transplant patients, but the association was less consistent in the outpatient setting.  
Table 2a Logistic regression analysis to predict whether or not dialysis patients incur any hospital 
costs 
 
 n (%) 
patient-years 
Dialysis inpatient  Dialysis outpatient 
 
Odds ratio 95% CI  Odds ratio 95% CI 
Constant  2.34* (2.18, 2.51)  18.09* (15.62, 20.95) 
Age group       
< 50 years 10,608 (21%) Reference   Reference  
50-64 years 13,330 (26%) 0.98 (0.91, 1.05)  1.26* (1.08, 1.46) 
65-75 years 15,393 (30%) 0.91* (0.85, 0.97)  1.01 (0.88, 1.17) 
> 75 years 11,243 (22%) 0.87* (0.81, 0.94)  0.82* (0.70, 0.96) 
Sex       
Male 31,450 (62%) Reference   - - 
Female 19,124 (38%) 1.10* (1.05, 1.16)  - - 
Years on dialysis       
1 15,869 (31%) Reference   Reference  
2 11,886 (23%) 0.59* (0.56, 0.62)  0.80* (0.73, 0.88) 
3 9,465 (19%) 0.50* (0.47, 0.52)  0.69* (0.62, 0.76) 
4 7,497 (15%) 0.58* (0.54, 0.62)  0.76* (0.67, 0.85) 
5 4,058 (8%) 0.61* (0.56, 0.67)  0.71* (0.62, 0.82) 
6 1,799 (4%) 0.65* (0.57, 0.74)  0.72* (0.59, 0.89) 
Dialysis modality       
Haemodialysis 39,730 (79%) Reference   Reference  
Peritoneal dialysis 10,844 (21%) 0.83* (0.79, 0.88)  2.36* (2.07, 2.69) 
Comorbidities       
Myocardial infarction  8,347 (17%) 1.22* (1.14, 1.31)  - - 
Congestive heart failure  8,801 (17%) 1.11* (1.04, 1.19)  0.88* (0.79, 0.98) 
Peripheral vascular disease 8,204 (16%) 1.33* (1.24, 1.42)  1.25* (1.12, 1.41) 
Cerebrovascular disease 5,459 (11%) 1.15* (1.07, 1.24)  0.86* (0.76, 0.97) 
Pulmonary 7,351 (15%) 1.26* (1.17, 1.35)  1.13* (1.01, 1.27) 
Liver 393 (1%) - -  - - 
Diabetes 19,167 (34%) 1.27* (1.21, 1.34)  1.64* (1.48, 1.81) 
Cancer 4,092 (8%) 1.22* (1.11, 1.33)  1.40* (1.20, 1.63) 
Hypertension 31,245 (62%) 1.09* (1.04, 1.14)  1.36* (1.23, 1.49) 
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Transplant  3,012 (6%) 1.11* (1.02, 1.21)  0.25* (0.21, 0.29) 
Recovered renal function 710 (1%) 0.82* (0.69, 0.96)  0.12* (0.10, 0.15) 
Death 7,528 (15%) 1.94* (1.81, 2.07)  0.16* (0.15, 0.18) 
Death first half following year 2,521 (5%) 2.61* (2.34, 2.92)  1.16 (0.93, 1.44) 
*p<0.05 
Table 2b Logistic regression analysis to predict whether or not transplant patients incur any hospital 
costs 
 n (%) 
patient-years 
Transplant inpatient  Transplant outpatient 
 
Odds ratio 95% CI  Odds ratio 95% CI 
Constant  1.89* (1.65, 2.16)  104.02* (72.08, 150.12) 
Age group       
< 35 years 3,352 (22%) Reference   - - 
36-45 years 3,950 (26%) 0.81* (0.72, 0.92)  - - 
46-55 years 3,886 (25%) 0.73* (0.64, 0.82)  - - 
> 55 years 4,037 (27%) 0.76* (0.67, 0.87)  - - 
Sex       
Male 9,575 (63%) Reference   Reference  
Female 5,650 (37%) 1.35* (1.22, 1.49)  1.53* (1.09, 2.16) 
Years following transplant       
1 4,511 (29%) Reference   Reference  
2 3,615 (24%) 0.21* (0.19, 0.23)  1.17 (0.85, 1.62) 
3 2,877 (19%) 0.18* (0.16, 0.20)  1.60* (1.06, 2.43) 
4 2,150 (14%) 0.19* (0.17, 0.22)  1.79* (1.06, 3.04) 
5 1,355 (9%) 0.19* (0.16, 0.23)  1.08 (0.64, 1.84) 
6 717 (5%) 0.18* (0.14, 0.22)  1.06 (0.45, 2.51) 
Transplant type       
Deceased donor 9,874 (65%) Reference   Reference  
Living donor 5,351 (35%) 0.82* (0.75, 0.90)  0.71 (0.49, 1.03) 
Comorbidities       
Myocardial infarction 1,238 (8%) 1.47* (1.24, 1.73)  - - 
Congestive heart failure  932 (6%) 1.48* (1.22, 1.79)  - - 
Peripheral vascular disease 1,676 (11%) 1.87* (1.62, 2.16)  1.56* (1.00, 2.42) 
Cerebrovascular disease 975 (6%) 1.38* (1.16, 1.65)  - - 
Pulmonary 2,050 (13%) 1.24* (1.09, 1.40)  - - 
Liver 119 (1%) 2.18* (1.37, 3.47)  - - 
Diabetes 4,000 (26%) 1.62* (1.46. 1.80)  1.80* (1.21, 2.66) 
Cancer 614 (4%) 1.62* (1.31, 2.01)  3.45* (1.32, 8.99) 
Hypertension 11,251 (74%) 1.33* (1.21, 1.46)  - - 
Graft failure 493 (3%) - -  0.02* (0.02, 0.03) 
Death 250 (2%) 1.62* (1.14, 2.31)  0.02* (0.01, 0.03) 
Death first half following year 79 (0.5%) 4.55* (2.47, 8.39)  - - 
*p<0.05 
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Part two: generalised linear models 
Generalised linear models with an identity link function and gamma distribution were fitted to the 
subset of patients with non-zero costs. The model results shown in Tables 3a and 3b include imputed 
values that were generated using the hybrid approach to predict missing costs due to administrative 
censoring.  
Mean inpatient costs were higher for dialysis patients compared to transplant patients with a trend 
towards decreasing costs in both patient groups over time. In contrast, mean outpatient costs were 
initially higher in the first year for transplant patients compared to dialysis patients, but decreased at a 
faster rate in subsequent years with dialysis outpatient costs overtaking those of transplant patients by 
the third year. 
For dialysis patients, cost differed by treatment modality; haemodialysis was associated with higher 
costs in the inpatient setting, whereas peritoneal dialysis was associated with higher costs in the 
outpatient setting. Similarly in the transplant datasets, living donor transplants were associated with 
lower costs in the inpatient setting (although not statistically significant) and higher costs in the 
outpatient setting.  
The increase in mean annual costs associated with various comorbidities ranged between £321 - 
£1,682 in the dialysis inpatient setting and between £264 and £2,093 in the transplant inpatient 
setting. Of the comorbidities included in the final models, peripheral vascular disease and diabetes 
were the only two that were consistently associated with significantly higher costs in both dialysis and 
transplant patients as well as in both inpatient and outpatient settings. The proportion of patients in 
both the dialysis and transplant datasets who had peripheral vascular disease was approximately 12% 
and the proportion who had diabetes was approximately 30%. 
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Table 3a Mean annual costs (£) for dialysis patients (generalised linear model)  
 Dialysis inpatient  Dialysis outpatient 
 Coeff 95% CI  Coeff 95% CI 
Constant 7782* (7423, 8140)  1379* (1331, 1428) 
Age group      
< 50 years Reference   Reference  
50-64 years -170 (-489, 149)  -25 (-79, 29) 
65-75 years -181 (-513, 151)  -167* (-219, -115) 
> 75 years -444* (-806, -83)  -320* (-376, -264) 
Sex      
Male Reference   - - 
Female 208* (-23, 439)  - - 
Years on dialysis      
1 Reference   Reference  
2 -1189* (-1487, -891)  -159* (-186, -131) 
3 -1434* (-1729, -1140)  -112* (-145, -80) 
4 -1848* (-2166, -1530)  -438* (-85, -1) 
5 -1709* (-2099, -1319)  -13 (-66, 40) 
6 -2270* (-2774, -1767)  134* (36, 232) 
Dialysis modality      
Haemodialysis Reference   Reference  
Peritoneal dialysis -612* (-838, -385)  334* (296, 373) 
Comorbidities      
Myocardial infarction 390* (96, 683)  - - 
Congestive heart failure  321* (58, 584)  -40 (-81, 0) 
Peripheral vascular disease 721* (423, 1019)  117* (66, 168) 
Cerebrovascular disease 506* (174, 838)  - - 
Pulmonary 412* (128, 696)  46 (0, 93) 
Liver 1682* (-161, 3524)  - - 
Diabetes 1191* (929, 1453)  248* (211, 284) 
Cancer - -  139* (72, 206) 
Hypertension - -  - - 
Transplant  -1863* (-2140, -1585)  -552* (-602, -501) 
Recovered renal function 1293* (513, 2073)  -348* (-454, -243) 
Death 2403* (2152, 2654)  -377* (-414, -341) 
Death first half following year 4415* (3926, 4904)  200* (138, 262) 
*p<0.05 
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Table 3b Mean annual costs (£) for transplant patients (generalised linear model) 
 Transplant inpatient Transplant outpatient 
 Coeff 95% CI Coeff 95% CI 
Constant 4735* (4331, 5138) 4053* (3961, 4145) 
Age group     
< 35 years Reference  Reference  
36-45 years -318 (-664, 29) -123* (-193, -53) 
46-55 years -310 (-676, 56) -151* (-224, -78) 
> 55 years -91 (-487, 306) -126* (-195, -57) 
Sex     
Male Reference  Reference  
Female 190 (-76, 455) 126* (76, 175) 
Years following transplant     
1 Reference  Reference  
2 -1576* (-1881, -1271) -2671* (-2731, -2610) 
3 -1919* (-2228, -1611) -2935* (-3000, -2869) 
4 -2138* (-2485, -1790) -3018* (-3088, -2948) 
5 -2061* (-2502, -1620) -3089* (-3166, -3011) 
6 -2654* (-3212, -2096) -3105* (-3204, -3006) 
Transplant type     
Deceased donor Reference  Reference  
Living donor -223 (-486, 39) 130* (78, 182) 
Comorbidities     
Myocardial infarction 641* (145, 1138) 130* (17, 242) 
Congestive heart failure  1248* (646, 1851) 159* (35, 284) 
Peripheral vascular disease 1222* (729, 1715) 256* (157, 354) 
Cerebrovascular disease 898* (271, 1524) 88 (-21, 197) 
Pulmonary 264 (-87, 616) 179* (99, 258) 
Liver 2093* (30, 4155) 524* (200, 849) 
Diabetes 1046* (734, 1359) 593* (515, 671) 
Cancer 485* (2, 969) 273* (134, 411) 
Hypertension 324* (56, 592) 144* (91, 197) 
Graft failure 2438* (1723, 3152) -309* (-451, -167) 
Death 4924* (3726, 6123) -216* (-426, -5) 
Death first half following year 5725* (3350, 8100) 629* (321, 936) 
*p<0.05 
 
Model performance and predicted costs 
Table 4 summarises observed and predicted mean annual cost estimates for each of the final two-part 
models. The results were compared with models that were developed based on complete-case 
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analyses, in which patients who were administratively censored were removed from the dataset. In 
each case, RMSE was found to be similar between the model based on complete-case analysis and the 
model that was developed using multiply imputed values.    
Table 4 Observed and predicted mean annual costs  
 
Number of 
observations 
(patient-years) 
Mean costs  
(std dev) 
RMSE 
Dialysis inpatient  
Observed   
46850 
£ 5581 (9440)  
Two-part model complete-case analysis £ 5576 (2120) 9202.92 
Two-part model hybrid imputed costs £ 5578 (2136) 9204.73 
Dialysis outpatient  
Observed   
46850 
£ 1202 (1348)  
Two-part model complete-case analysis £ 1196 (343) 1291.19 
Two-part model hybrid imputed costs £ 1203 (345) 1291.22 
Transplant inpatient  
Observed   
11710 
£ 2398 (4675)  
Two-part model complete-case analysis £ 2390 (1931) 4278.45 
Two-part model hybrid imputed costs £ 2468 (1958) 4279.87 
Transplant outpatient  
Observed   
11710 
£ 2388 (2007)  
Two-part model complete-case analysis £ 2383 (1332) 1459.10 
Two-part model hybrid imputed costs £ 2447 (1386) 1458.98 
 
As the motivation for the analysis was to predict annual hospital costs that can be used inputs in an 
economic evaluation, the appendix provides a worked example of how the regression results 
presented above can be used for this purpose. 
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DISCUSSION 
Previous examples of economic evaluations that have compared dialysis and transplantation as 
treatment alternatives for patients with ERF have taken a variety approaches to estimating costs. For 
transplant costs, it is common practice to estimate a cost for the first year of treatment that reflects the 
cost of surgery, and then assume a constant annual cost to capture resource use such as 
immunosuppressive therapy or outpatient visits in subsequent years [15-20]. For dialysis costs, some 
studies restrict the analysis to the cost of routine dialysis only, while others include the cost of 
hospitalisations, management of complications or drugs. Other than taking into account the cost of 
vascular access at the start of dialysis, annual costs for dialysis patients are often assumed to be 
constant [18,16]. However, there are examples of economic evaluations that have introduced an 
element of variation in costs among dialysis patients by considering factors such as age or time on 
treatment: de Wit et al [19] presented separate estimates of hospital costs by age group based on data 
collected at 13 Dutch dialysis centres; Haller et al [15] analysed patient-level cost data from a hospital 
in Austria and presented separate cost estimates for dialysis patients in the first year, second year and 
subsequent years of treatment.  None of these previous studies have simultaneously considered the 
impact of treatment modality, length of time on treatment, age and comorbidities on costs. 
Collection of patient-level cost data is a resource intensive exercise. The linkage of HES data to 
UKRR data provides a rare opportunity to analyse a large existing dataset to explore variations in 
hospital costs specifically among patients receiving RRT in England. HES is, to our knowledge, the 
most complete source of routinely collected information on admissions and attendances at NHS 
hospitals in England and linkage to UKRR data facilitates simultaneous exploration of multiple 
patient and treatment-related factors that may affect costs. The approach to analysing the linked 
dataset was guided by both the features of the data and the intended use of the results. In this case, the 
primary objective of the analysis was to predict annual costs for patients with different characteristics 
for use as inputs in an economic evaluation.  Additionally, there were three main features of the cost 
data that needed to be addressed: 1) missing data due to administrative censoring, 2) the proportion of 
observations with zero costs and 3) positively skewed distributions.  
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Multiple imputation was carried out to address the issue of administrative censoring. Multiple 
imputation has the advantage of making use of all available observed data, while allowing for 
uncertainty about the missing values [21,22]. In this analysis, the models based on complete cases and 
the models that included imputed values were very similar, providing confidence that missing data 
due to administrative censoring did not bias the estimates of cost. This suggests that a complete-case 
analysis would have been sufficient, but it is unclear if this conclusion can be generalised beyond our 
dataset. There is a growing body of literature describing other methods to address the common issue 
of censoring of cost data [23-27]. However, given that the primary objective of the current analysis 
was to estimate annual (as opposed to lifetime) costs and that cost histories detailing the timing of 
individual hospital events were not available in the current extract of the dataset, approaches based on 
survival analysis techniques were not pursued.  
The issues of zero costs and positively skewed distributions were addressed by adopting a two-part 
approach in which a logistic regression was fitted to predict the probability of incurring any hospital 
costs, followed by fitting a GLM to estimate the level of cost for patients with at least one admission 
or visit. A potential advantage of the two-part approach is that covariates that are determined to be 
significant in part one of the model do not have to be the same as those that determine the level of cost 
in part two. In the present analyses, there was general consistency in terms of the covariates that were 
included in part one and part two of the final inpatient cost models, but less agreement in the 
outpatient setting where the percentage of zero costs was lower.   
The results of this analysis highlight a number of findings that are relevant when considering 
variations in hospital costs for patients on RRT in the context of economic evaluation. Firstly, while 
the cost of transplant surgery can be viewed as a one-time event and the cost of maintenance dialysis 
sessions generally remains constant from week to week and year to year, hospital costs for patients on 
RRT showed a decreasing trend over time that extended beyond the first two years on RRT. A 
plausible explanation for this trend is that patients who survive longer on therapy are on average fitter 
and healthier and required fewer hospital visits. Secondly, age did not have a consistent effect on 
costs across all treatment modalities and hospital settings and, in contrast to the approach taken in the 
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economic evaluation by de Wit et al [19], the current analysis suggests that, controlling for other 
factors, increasing age alone may be associated with lower rather than higher costs. Thirdly, many of 
the comorbidities included in the analysis were found to be significant predictors of hospital costs and 
had a bigger impact than age in the estimation of costs for patients on RRT.  
In the absence of evidence to the contrary, it is perhaps most natural to adopt an assumption that costs 
remain constant either over time or between subgroups of patients with different characteristics. 
However, if appropriate patient-level data sources can be identified, a more detailed understanding of 
patient characteristics and treatment factors that influence costs can help improve the accuracy with 
which costs are estimated in the context of economic evaluations.  
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APPENDIX: A WORKED EXAMPLE TO PREDICT HOSPITAL COSTS BASED ON THE 
FINAL TWO-PART MODEL 
To estimate annual inpatient costs for a 55-year-old male patient with diabetes who has been on 
haemodialysis for three years: 
Part 1: probability of incurring any inpatient cost > £0 
Taking the natural log of the odds ratios in Table 2a, calculate log odds of incurring any inpatient cost 
CONSTANT + (β1 ×  AGEGROUP50 − 64) +  (β2 ×  YEAR3) + (β3 ×  DIABETES)  
= 0.850 + (−0.022 × 1) +  (−0.702 × 1) +  (0.242 × 1) = 0.368 
Calculate probability from log odds 
𝑒𝑥𝛽  (1 +  𝑒𝑥𝛽) =  𝑒0.368  (1 + 𝑒0.368) = 0.591⁄⁄  
Part 2: estimate level of inpatient cost based on coefficients in Table 3a  
CONSTANT + (β1 ×  AGEGROUP50 − 64) +  (β2 ×  YEAR3) + (β3 ×  DIABETES) 
= 7782 + (−170 × 1) +  (−1434 × 1) +  (1191 × 1) = 7368 
Combine parts 1 and 2: multiply estimated level of inpatient cost by probability of incurring any cost 
7368 × 0.591 = £4,354 
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